Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update (2022)

Peer-Reviewed Study · Nancy N. Baxter; Erin B. Kennedy; Emily Bergsland; Jordan Berlin; Thomas J. George; Sharlene Gill; et al.; Meyerhardt JA · March 10, 2022

Nancy N. Baxter et al., 2022-03-10: Current ASCO guidance after systematic review of 21 observational studies and 6 RCTs: no routine adjuvant chemotherapy for average-risk stage II; offer it for T4; consider it for other high-risk features; do not routinely add oxaliplatin; do not routinely give it for dMMR/MSI tumours.

Adjuvant chemotherapy (ACT) is not routinely recommended for patients with stage II colon cancer who are not in a high-risk subgroup.

Abstract, Recommendations

Nancy N. Baxter et al., 2022-03-10: Current ASCO guidance after systematic review of 21 observational studies and 6 RCTs: no routine adjuvant chemotherapy for average-risk stage II; offer it for T4; consider it for other high-risk features; do not routinely add oxaliplatin; do not routinely give it for dMMR/MSI tumours. Funding: ASCO. COI: extensive disclosures listed in the article – e.g. Bergsland (Amgen, Merck research funding; More Health), Berlin (Bayer, Lilly, Pfizer and others), George (BMS, Merck, AstraZeneca), Gill (Taiho, Amgen, Roche), Mahmoud (employed by Johnson & Johnson). Comparator: guideline, not a trial. This is the primary source for 'low-risk stage II patients do not routinely get chemo'. ascopubs.org is paywalled to automated access; abstract and full disclosure block read on the PubMed record. Study type: review.